Prevail Therapeutics Inc. Common Stock
PRVL
PRVL was delisted on the 21st of January, 2021.
67 hedge funds and large institutions have $421M invested in Prevail Therapeutics Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 13 reducing their positions, and 5 closing their positions.
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
92% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 13
24% more capital invested
Capital invested by funds: $339M → $421M (+$81.9M)
16% more funds holding
Funds holding: 58 → 67 (+9)
1.2% more ownership
Funds ownership: 81.42% → 82.62% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$15.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$13.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.61M |
| 4 |
BlackRock
New York
|
+$4.81M |
| 5 |
Morgan Stanley
New York
|
+$4.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$29M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.5M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$5.26M |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$1.31M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$718K |
PRVL Hedge Fund Activity: Q2 2020 in Review
67 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q2 2020, worth a combined $421M — up 24% from $339M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PRVL positions and 5 closed out — a net gain of 9 holders — while 25 added to existing stakes and 13 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $15.8M. The largest seller was EcoR1 Capital, cutting an estimated $29M.
- 67 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q2 2020, up from 58 in Q1 2020.
- Funds reported $421M of Prevail Therapeutics Inc. Common Stock stock for Q2 2020, up 24% quarter-over-quarter.
- 14 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q2 2020 and 5 closed out, a net change of +9 holders.
- The largest Prevail Therapeutics Inc. Common Stock buyer in Q2 2020 was Avidity Partners Management, an estimated $15.8M added.
- The largest Prevail Therapeutics Inc. Common Stock seller in Q2 2020 was EcoR1 Capital, an estimated $29M sold.
Based on aggregated 13F filings for Q2 2020.